Alleviant ALLAY-HF Study

Brief summary (registry, in English)

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

What you commit to

• Study type: Interventional
• Planned participants: 700
• From 10 Jan 2023 to the primary completion date, 1 Dec 2027
• 93 sites in 14 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (93)

Sites in registry order. Pick your city on the disease page to sort them by distance.